Report: Mega-Mergers: Executing Change in the Pharma Industry TOC

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Taking Action Via Acquisition and Merger
Mega-Mergers: Restructuring the Corporate Landscape, 2000-2009
Pfizer Chooses Wyeth for a 2009 Mega-Merger
- Financial Considerations
- Product Portfolios and Prospects
- Advantages of a Pfizer/Wyeth Merger
- Lessons Learned from Previous Acquisitions
- Pfizer' s Enhanced Interest in Generics/Biosimilars
- Healthcare Reform in the United States
Can Roche Prevent Itself from Stifling Genentech?
- Financial Considerations
- Product Portfolios and Prospects
- Differing Views of the Merger
- Will Roche Be Able to Manage the Acquisition Effectively?
Merck & Co. Covets Schering-Plough
- Reengineering Merck & Co.
- Proposed Acquisition of Schering-Plough
- Short-Term Fix
GlaxoSmithKline' s Prodigious Number of Smaller-Scale Deals
- Mega-Mergers: Captor or Prey - Who Is Next?
- Outlook - The Herd Mentality

1. Mergers and Acquisitions Valued at More Than $2 Billion, 2007-2009
2. Patent Expiry Years for Pfizer' s Top-Selling Products, 2008
3. Roche' s Critical Dependence on Genentech for Product Revenues, 2008
4. Genentech' s Five Highest-Selling Products: No Near-Term U.S. Patent Expiries
5. Merck & Co.' s New Commercial Business Model: Deliver More for Less
6. Merck & Co.' s Late-Stage Pipeline, December 2008
7. Nine Additional Phase III Candidates from Schering-Plough
8. GlaxoSmithKline' s Emerging Market and OTC Acquisitions, 2008 and 2009
9. GlaxoSmithKline' s Therapy-Area Licenses and Acquisitions, 2008 and 2009

1. Merger and Acquisition Size Distribution, 2007-2009
2. Consolidation in the Pharma Industry, 2000-2009
3. Pfizer' s Total Revenues by Business Segment and Geography, 2006-2008
4. Wyeth' s Financials, 2006-2008
5. Worldwide Sales of Wyeth' s Top-Selling Products, 2008
6. Roche Group' s Worldwide Sales, 2007 and 2008
7. Merck & Co. and Schering-Plough: Combined Therapy-Area Sales, 2008
8. Market Capitalization of the Largest Pharma, Specialty Pharma, and Biotech Companies

Mega-Mergers: Executing Change in the Pharma Industry